[HTML][HTML] NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hepatocellular carcinoma (HCC) can have viral or non-viral causes,,,–. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
[HTML][HTML] NASH limits anti-tumour surveillance in immunotherapy-treated HCC
D Pfister, NG Nez, R Pinyol, O Govaere, M Pinter… - paper.sciencenet.cn
德国癌症研究中心Mathias Heikenwalder, Josep M. Llovet 等研究人员合作发现, NASH
限制免疫治疗肝癌中的抗肿瘤监测. 2021 年3 月24 日, 国际知名学术期刊《 自然》 …
限制免疫治疗肝癌中的抗肿瘤监测. 2021 年3 月24 日, 国际知名学术期刊《 自然》 …
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
D Pfister, NG Nunez, R Pinyol, O Govaere, M Pinter… - NATURE, 2021 - flore.unifi.it
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter… - Nature, 2021 - hal.science
Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
D Pfister, NG Nunez, R Pinyol, O Govaere… - …, 2021 - tobias-lib.ub.uni-tuebingen.de
NASH limits anti-tumour surveillance in immunotherapy-treated HCC NASH limits anti-tumour
surveillance in immunotherapy-treated HCC DSpace Repositorium (Manakin basiert) Einloggen …
surveillance in immunotherapy-treated HCC DSpace Repositorium (Manakin basiert) Einloggen …
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter… - Nature, 2021 - boris.unibe.ch
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1-5. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter… - Nature, 2021 - econpapers.repec.org
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter… - Nature, 2021 - scholar.nycu.edu.tw
Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
D Pfister, NG Núñez, R Pinyol, O Govaere… - …, 2021 - research.uni-luebeck.de
Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
D Pfister, NG Nunez, R Pinyol, O Govaere, M Pinter… - Nature, 2021 - pure.mpg.de
Hepatocellular carcinoma (HCC) can have viral or non-viral causes (1-5). Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …